You have 8 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Non-canonical Notch ligand

Showing 26 - 50 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Malocclusion, Dementia Trial in Granada (Dental occlusion restoration, Orthodontic treatment of malocclusion)

Active, not recruiting
  • Malocclusion
  • Dementia
  • Dental occlusion restoration
  • Orthodontic treatment of malocclusion
  • Granada, Spain
    Facultad de Odontología
Dec 2, 2022

Idiopathic Pulmonary Fibrosis Trial in Palo Alto (PLN-74809, Knottin tracer)

Completed
  • Idiopathic Pulmonary Fibrosis
  • Palo Alto, California
    Stanford Medical Center
Nov 15, 2022

Non-Squamous NSCLC, Squamous NSCLC Trial in Worldwide (Atezolizumab (MPDL3280A) [TECENTRIQ], an engineered anti-PDL1 antibody,

Completed
Has Results
  • Non-Squamous Non-Small Cell Lung Cancer, Squamous Non-Small Cell Lung Cancer
  • Atezolizumab (MPDL3280A) [TECENTRIQ], an engineered anti-PDL1 antibody
  • +4 more
  • La Jolla, California
  • +141 more
Apr 21, 2022

C9orf72 Amyotrophic Lateral Sclerosis (ALS), Frontotemporal Dementia Trial in Gainesville (Metformin)

Recruiting
  • C9orf72 Amyotrophic Lateral Sclerosis (ALS)
  • Frontotemporal Dementia
  • Gainesville, Florida
    UF Health at the University of Florida
Sep 7, 2021

NSCLC (NSCLC) Trial in Shanghai (Tumor treating fields(EFE-P100), Docetaxel injection)

Not yet recruiting
  • Non-small Cell Lung Cancer (NSCLC)
  • Tumor treating fields（EFE-P100）
  • Docetaxel injection
  • Shanghai, China
    Shanghai Pulmonary Hospital
Dec 21, 2022

NSCLC Trial in Worldwide (Atezolizumab (MPDL3280A), an engineered anti-PD-L1 antibody, Docetaxel)

Completed
  • Carcinoma, Non-Small-Cell Lung
  • Atezolizumab (MPDL3280A), an engineered anti-PD-L1 antibody
  • Docetaxel
  • Beijing, China
  • +37 more
Jan 9, 2023

NSCLC, Metastatic NSCLC Trial (Tislelizumab, BGB-A445, LBL-007)

Not yet recruiting
  • Non-small Cell Lung Cancer
  • Metastatic Non-small Cell Lung Cancer
  • (no location specified)
Dec 14, 2022

Triple Negative Breast Cancer, PD-L1 Negative Trial in Puerto Rico, United States (Sacituzumab Govitecan-hziy, Paclitaxel,

Recruiting
  • Triple Negative Breast Cancer
  • PD-L1 Negative
  • Sacituzumab Govitecan-hziy
  • +4 more
  • Anchorage, Alaska
  • +231 more
Jan 17, 2023

Tumors, Head and Neck Trial in Worldwide (Dostarlimab, Belrestotug, GSK6097608)

Not yet recruiting
  • Neoplasms, Head and Neck
  • New Haven, Connecticut
  • +121 more
Oct 3, 2023

Periodontal Diseases Trial in Baghdad (Root surface debridement)

Enrolling by invitation
  • Periodontal Diseases
  • Root surface debridement
  • Baghdad, Iraq
    College of Dentistry, University of Baghdad
Dec 12, 2022

Extensive Stage Small Cell Lung Cancer Trial (Tarlatamab, Carboplatin, Etoposide)

Recruiting
  • Extensive Stage Small Cell Lung Cancer
  • Los Angeles, California
  • +37 more
Feb 1, 2023

NSCLC (NSCLC) Trial in Worldwide (Tislelizumab, Docetaxel, Sitravatinib)

Recruiting
  • Non-Small Cell Lung Cancer (NSCLC)
  • Tucson, Arizona
  • +112 more
Nov 9, 2022

Alopecia Areata Trial in Aswan (Calcipotriol)

Recruiting
  • Alopecia Areata
  • Aswan, Egypt
    Faculty of Dentistary - Aswan University
Jul 21, 2023

Vascular Diseases Trial in Mar del Plata (Finger photoplethysmography)

Recruiting
  • Vascular Diseases
  • Finger photoplethysmography
  • Mar del Plata, Buenos Aires, Argentina
  • +1 more
Jan 3, 2022

Lung Cancer, Non-Small Cell Trial in Worldwide (Dostarlimab, Pembrolizumab, Chemotherapy)

Active, not recruiting
  • Lung Cancer, Non-Small Cell
  • Lone Tree, Colorado
  • +65 more
Jun 26, 2022

NSCLC Trial (pembrolizumab, carboplatin, paclitaxel)

Active, not recruiting
Has Results
  • Non-small Cell Lung Cancer
  • pembrolizumab
  • +3 more
  • (no location specified)
Aug 18, 2022

Fibronectin Type ? Domain Containing Protein 5 \ Irsin Gene

Recruiting
  • Hepatitis B, Chronic
  • genotyping
  • Sohag, Egypt
    Sohag university Hospital
Sep 4, 2023

Cancer, Breast, Cancer, Lung, Cancer of Pancreas Trial in Fairfax, Beijing (CBP-1019)

Active, not recruiting
  • Cancer, Breast
  • +4 more
  • Fairfax, Virginia
  • +1 more
Apr 13, 2023

Lung Cancer, Non-Small Cell Trial in Worldwide (Pembrolizumab, Dostarlimab, GSK4428859A)

Recruiting
  • Lung Cancer, Non-Small Cell
  • Ciudad Autónoma de Buenos Aires, Buenos Aires, Argentina
  • +14 more
Dec 26, 2022

Tendinopathy Trial in Lyon (Endoscopic tenotomy surgery of the iliopsoas tendon)

Not yet recruiting
  • Tendinopathy
  • Endoscopic tenotomy surgery of the iliopsoas tendon
  • Lyon, France
    Clinique de la Sauvegarde
Jul 17, 2023

Critical Asymptomatic Carotid Artery Disease, Non-Critical Asymptomatic Carotid Artery Disease Trial in Birmingham

Recruiting
  • Critical Asymptomatic Carotid Artery Disease
  • Non-Critical Asymptomatic Carotid Artery Disease
  • Birmingham, Alabama
    UAB
Dec 13, 2022

Peri-Implantitis Trial in Van (Er, Cr: YSGG laser-assisted non-surgical mechanical therapy, Non-surgical mechanical therapy)

Completed
  • Peri-Implantitis
  • Er, Cr: YSGG laser-assisted non-surgical mechanical therapy
  • Non-surgical mechanical therapy
  • Van, Turkey
    Nazli Zeynep Alpaslan
Sep 13, 2023

Advanced or Metastatic Solid Tumors Trial (PMC-309 monotherapy, PMC-309 Dose Escalation in Combination with Pembrolizumab,

Not yet recruiting
  • Advanced or Metastatic Solid Tumors
  • PMC-309 monotherapy
  • +2 more
  • (no location specified)
Jul 19, 2023

Advanced Non-small-cell Lung Cancer Trial in Shanghai (AK112, Pembrolizumab)

Not yet recruiting
  • Advanced Non-small-cell Lung Cancer
  • Shanghai, China
    Shanghai Pulmonary Hospital
Aug 12, 2022

TNBC - Triple-Negative Breast Cancer Trial in Brussels (Ga-PSMA PET/CT)

Recruiting
  • TNBC - Triple-Negative Breast Cancer
  • Ga-PSMA PET/CT
  • Brussels, Belgium
    Institut Jules Bordet
Sep 26, 2023